Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Immunoprecise Antibodies Ltd
(NQ:
IPA
)
1.320
+0.130 (+10.92%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunoprecise Antibodies Ltd
< Previous
1
2
3
4
Next >
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
April 22, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
April 12, 2024
Via
ACCESSWIRE
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
March 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
March 20, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
March 14, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
March 08, 2024
Via
ACCESSWIRE
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
March 07, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
March 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
February 13, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
January 10, 2024
Via
ACCESSWIRE
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
December 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Closing of $1.265 Million Public Offering of Common Shares
December 08, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Welcomes Mitch Levine To Its Board Of Directors, To Announce Quarterly Results On December 14
December 07, 2023
Via
ACCESSWIRE
IPA Announces Pricing of $1.1 Million Public Offering of Common Shares
December 06, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Proposed Public Offering of Common Shares
December 05, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Announces Key Board and Board Committee Chair Appointments and Second Quarter 2024 Earnings Release Call
November 27, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise’s BioStrand(R) Unifies Diverse Data Modalities, Launches AI-Driven Platform For Enhanced Drug Discovery
November 22, 2023
Via
ACCESSWIRE
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
November 13, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
October 25, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Provides Update on Growth Strategy and Recent Share Price Movement
October 23, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Overcoming the Information Integration Dilemma: Revolutionizing The Fusion Of Complex Biological Data
October 20, 2023
Via
ACCESSWIRE
How ImmunoPrecise Antibodies Is Leveraging AI To Revolutionize Antibody Research
October 13, 2023
Via
ACCESSWIRE
ImmunoPrecise Antibodies Announces CFO Transition
September 19, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024
September 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023
September 08, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Announces Board Refreshment
September 05, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA Responds to 13D Filing
August 09, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Invites Investors and Stakeholders to Exclusive Interview with Market Radius Research
July 14, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023
July 07, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
June 29, 2023
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.